Innovations In Clinical Neuroscience

MAY-JUN 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 23 of 35

Innovations in CLINICAL NEUROSCIENCE [ V O L U M E 1 4 , N U M B E R 5 – 6 , M A Y – J U N E 2 0 1 7 ] 24 Pharmacol Ther. 2011;89(3):352–353. 13. Gonzalez I, Penas-Lledo EM, Perez B, et al. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics. 2008;9(7):833–840. 14. Yu AM, Idle JR, Byrd LG, et al. Regeneration of serotonin from 5- methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics. 2003;13(3):173–181. 15. Travica S, Pors K, Loadman PM, et al. Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin Cancer Res. 2013;19(11):2952–2961. 16. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw Hill; 1996:3–27. 17. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60(2):284–295.oooooo 18. Griese EU, Zanger UM, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998;8(1):15–26. 19. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200–1205. 20. Penas-Lledo E, Guillaume S, Naranjo Me, et al. A combined high CYP2D6- CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances. Pharmacogenomics. 2015;(2):172–176.

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - MAY-JUN 2017